Role of Fine Needle Aspiration Cytology in the Diagnosis of Gynecologic Tumors

Goyal A.

Author affiliations

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA

Acta Cytologica 2023;67:1–17

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Fine Needle Aspiration

Received: September 22, 2022
Accepted: January 17, 2023
Published online: March 14, 2023
Issue release date:

Number of Print Pages: 17
Number of Figures: 9
Number of Tables: 1

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Abstract

Background: The tumors involving the gynecologic tract encompass a wide range of lesions including those of epithelial, mesenchymal, sex cord-stromal, and germ cell origin. Amongst the carcinomas of tubo-ovarian origin, high-grade serous carcinoma is the most common malignancy. The primary role of fine needle aspiration (FNA) cytology in the management of gynecologic tract malignancies is in the diagnosis of their recurrences/metastases. In patients presenting with advanced disease, the cytology specimen may be the initial or the only sampling performed before the initiation of treatment. Summary: This review will discuss the cytologic findings of various gynecologic tract neoplasms with regard to their morphologic features, differential diagnoses, and the ancillary studies that can assist in their recognition. Key Messages: FNA cytology serves as a valuable tool in the diagnosis and management of gynecologic tract malignancies. However, making an accurate diagnosis of these entities, especially on limited cytology specimens, can be challenging. Awareness regarding the morphologic spectrum of these tumors, their potential mimics, and the ancillary studies that can be employed to refine their characterization, can assist in arriving at the correct diagnosis.

© 2023 S. Karger AG, Basel

References National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. (version 4.2022). Available from: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. McCluggage WG, Lax SF, Longacre TA, Malpica A, Soslow RA. Chapter 1: tumours of the ovary: introduction. WHO classification of tumours editorial board. Female genital tumours. Lyon, France: International Agency for Research on Cancer; 2020. p. 32–3. Graham L. ACOG releases guidelines on management of adnexal masses. Am Fam Physician. 2008 May 1;77(9):1320–3. Zhou AG, Levinson KL, Rosenthal DL, VandenBussche CJ. Performance of ovarian cyst fluid fine-needle aspiration cytology. Cancer Cytopathol. 2018 Feb;126(2):112–21. Layfield LJ, Berek JS. Fine-needle aspiration cytology in the management of gynecologic oncology patients. Cancer Treat Res. 1994;70:1–13. Freedman OC, Dodge J, Shaw P, Oza AM, Bernadini M, Klachook S, et al. Diagnosis of epithelial ovarian carcinoma prior to neoadjuvant chemotherapy. Gynecol Oncol. 2010 Oct;119(1):22–5. Wang D, Zhang G, Peng C, Shi Y, Shi X. Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study. J Ovarian Res. 2021 Mar 27;14(1):49. Bansal A, Srinivasan R, Rohilla M, Sundaram A, Rai B, Rajwanshi A, et al. Morphologic and immunocytochemical features of high-grade serous carcinoma of ovary in ascitic fluid effusion and fine-needle aspiration cytology. Am J Clin Pathol. 2020 Jun 8;154(1):103–14. Cibas ES. Ovary. In: Cibas ES, Ducatman BS, editors. Cytology – diagnostic principles and correlates Elsevier Inc; 2021. p. 520–37. Ordóñez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol. 2006 Jan;19(1):34–48. Ordóñez NG. Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol. 2013 Apr;26(4):553–62. Köbel M, Luo L, Grevers X, Lee S, Brooks-Wilson A, Gilks CB, et al. Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions. Int J Gynecol Pathol. 2019 Jul;38(4):353–62. Köbel M, Rahimi K, Rambau PF, Naugler C, Le Page C, Meunier L, et al. An immunohistochemical algorithm for ovarian carcinoma typing. Int J Gynecol Pathol. 2016 Sep;35(5):430–41. Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016 Jul 13;2(4):247–58. Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, et al. The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors. Mod Pathol. 2013 Sep;26(9):1255–63. Beirne JP, McArt DG, James JA, Salto-Tellez M, Maxwell P, McCluggage WG. p16 as a prognostic indicator in ovarian/tubal high-grade serous carcinoma. Histopathology. 2016 Mar;68(4):615–8. Ordóñez NG. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas. Hum Pathol. 2005 Nov;36(11):1163–7. Chapel DB, Husain AN, Krausz T, McGregor SM. PAX8 expression in a subset of malignant peritoneal mesotheliomas and benign mesothelium has diagnostic implications in the differential diagnosis of ovarian serous carcinoma. Am J Surg Pathol. 2017 Dec;41(12):1675–82. Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, et al. Principles of analytic validation of immunohistochemical assays: guideline from the college of American pathologists pathology and laboratory quality center. Arch Pathol Lab Med. 2014 Nov;138(11):1432–43. Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, et al. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: further evidence of relative chemoresistance. Gynecol Oncol. 2020 Sep;158(3):653–8. Razack R, Van der Merwe H, Schubert P. Fine needle aspiration cytology of a nodal low-grade serous neoplasm: a case report of low-grade serous carcinoma arising from a serous borderline tumour with cyto-histological correlation. Cytopathology. 2017 Aug;28(4):333–6. Chen L, Butler KA, Bell DA. Fine needle aspiration cytology of cervical lymph node involvement by ovarian serous borderline tumor. Cytojournal. 2016 Jul 27;13:16. Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003 Mar 19;95(6):484–6. Baker PM, Clement PB, Young RH. Malignant peritoneal mesothelioma in women: a study of 75 cases with emphasis on their morphologic spectrum and differential diagnosis. Am J Clin Pathol. 2005 May;123(5):724–37. Patel NP, Taylor CA, Levine EA, Trupiano JK, Geisinger KR. Cytomorphologic features of primary peritoneal mesothelioma in effusion, washing, and fine-needle aspiration biopsy specimens: examination of 49 cases at one institution, including post-intraperitoneal hyperthermic chemotherapy findings. Am J Clin Pathol. 2007 Sep;128(3):414–22. Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2018 Jan;142(1):89–108. Leblay N, Leprêtre F, Le Stang N, Gautier-Stein A, Villeneuve L, Isaac S, et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J Thorac Oncol. 2017 Apr;12(4):724–33. Offin M, Yang SR, Egger J, Jayakumaran G, Spencer RS, Lopardo J, et al. Molecular characterization of peritoneal mesotheliomas. J Thorac Oncol. 2022 Mar;17(3):455–60. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol. 2008 Jun;21(6):742–7. Krasinskas AM, Bartlett DL, Cieply K, Dacic S. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Mod Pathol. 2010 Apr;23(4):531–8. Sidana A, Kadakia M, Friend JC, Krane LS, Su D, Merino MJ, et al. Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. Urol Oncol. 2017 Mar;35(3):114.e9–14. Misdraji J, Carr NJ, Pai RK, Vang R. Chapter 3: pseudomyxoma peritonei. WHO classification of tumours editorial board. Female genital tumours. Lyon, France: International Agency for Research on Cancer; 2020. p. 211–3. Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016 Mar;40(3):419–32. Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019 Dec;32(12):1834–46. Witkowski L, Goudie C, Foulkes WD, McCluggage WG. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary): a review with recent developments on pathogenesis. Surg Pathol Clin. 2016 Jun;9(2):215–26. Aggarwal D, Gupta P, Chhabra P, Peters NJ, Bansal D, Srinivasan R, et al. Small cell carcinoma of ovary, hypercalcemic type: cytologic, histopathologic, and immunohistochemical landscapes of a rare case. J Pediatr Adolesc Gynecol. 2021 Feb;34(1):98–102. Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, et al. Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. Histopathology. 2016 Nov;69(5):727–38. McCluggage WG, Witkowski L, Clarke BA, Foulkes WD. Clinical, morphological and immunohistochemical evidence that small-cell carcinoma of the ovary of hypercalcaemic type (SCCOHT) may be a primitive germ-cell neoplasm. Histopathology. 2017 Jun;70(7):1147–54. Rabban JT, Buza N, Devouassoux-Shisheboran M, Huntsman DG, Kommoss F. Chapter 1: adult granulosa cell tumour. WHO classification of tumours editorial board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. p. 105–6. Wilson MK, Fong P, Mesnage S, Chrystal K, Shelling A, Payne K, et al. Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up. Gynecol Oncol. 2015 Aug;138(2):285–91. Edmund LN, Salama AM, Murali R. Cytologic features of sex cord-stromal tumors in women. Cancer Cytopathol. 2022 Jan;130(1):55–71. Al-Agha OM, Huwait HF, Chow C, Yang W, Senz J, Kalloger SE, et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol. 2011 Apr;35(4):484–94. Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, et al. The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary. Mod Pathol. 2010 Nov;23(11):1477–85. Hodgson A, Kim V, Murali R. Cytologic features of gynecologic germ cell tumors and carcinomas exhibiting germ cell tumor differentiation. Cancer Cytopathol. 2022 Dec 27. Epub ahead of print Johnson DN, Barroeta JE, Antic T, Lastra RR. Cytomorphologic features of metastatic endometrioid carcinoma by fine needle aspiration. Diagn Cytopathol. 2018 Feb;46(2):105–10. Song SJ, McGrath CM, Yu GH. Fine-needle aspiration cytology of endometriosis. Diagn Cytopathol. 2017 Apr;45(4):359–63. Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40–63. Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013 Dec;26(12):1594–604. Chen W, Husain A, Nelson GS, Rambau PF, Liu S, Lee CH, et al. Immunohistochemical profiling of endometrial serous carcinoma. Int J Gynecol Pathol. 2017 Mar;36(2):128–39. Atahan S, Ekinci C, Içli F, Erdoğan N. Cytology of clear cell carcinoma of the female genital tract in fine needle aspirates and ascites. Acta Cytol. 2000 Nov-Dec;44(6):1005–9. McConechy MK, Hoang LN, Chui MH, Senz J, Yang W, Rozenberg N, et al. In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. J Pathol Clin Res. 2015 Apr 9;1(3):173–85. Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol. 1995 Jun;19(6):666–74. Ventura KC, Filipowicz EA, Molina CP, Sawh RN, Logroño R. Diagnosis of recurrent uterine carcinosarcoma by fine-needle aspiration cytology: report of a case. Diagn Cytopathol. 2000 Aug;23(2):108–13. Akbari AH, Wang L, Soslow RA, Murali R. Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium. Cancer Cytopathol. 2021 Feb;129(2):121–31. Kolin DL, Quick CM, Dong F, Fletcher CDM, Stewart CJR, Soma A, et al. SMARCA4-deficient uterine sarcoma and undifferentiated endometrial carcinoma are distinct clinicopathologic entities. Am J Surg Pathol. 2020 Feb;44(2):263–70. Ramalingam P, Masand RP, Euscher ED, Malpica A. Undifferentiated carcinoma of the endometrium: an expanded immunohistochemical analysis including PAX-8 and basal-like carcinoma surrogate markers. Int J Gynecol Pathol. 2016 Sep;35(5):410–8. Mills AM, Longacre TA. Smooth muscle tumors of the female genital tract. Surg Pathol Clin. 2009 Dec;2(4):625–77. Tirumani SH, Deaver P, Shinagare AB, Tirumani H, Hornick JL, George S, et al. Metastatic pattern of uterine leiomyosarcoma: retrospective analysis of the predictors and outcome in 113 patients. J Gynecol Oncol. 2014 Oct;25(4):306–12. Pappa L, Zagorianakou N, Kitsiou E, Sintou-Mantela E, Bafa M, Malamnou-Mitsi V. Breast metastasis from uterine leiomyosarcoma diagnosed by fine needle aspiration: a case report. Acta Cytol. 2008 Jul–Aug;52(4):485–9. Weiss SW. Smooth muscle tumors of soft tissue. Adv Anat Pathol. 2002 Nov;9(6):351–9. Kim K-R, Lax SF, Lazar AJ, Longacre TA, Malpica A, Matias-Guiu X, et al. Chapter 6: tumors of the uterine corpus. WHO classification of tumours editorial board. Female genital tumours. Lyon (France): International Agency for Research on Cancer; 2020. p. 287–91. Policarpio-Nicolas ML, Cathro HP, Kerr SE, Stelow EB. Cytomorphologic features of low-grade endometrial stromal sarcoma. Am J Clin Pathol. 2007 Aug;128(2):265–71. Ginter PS, Pirog EC, Hoda RS. High grade endometrial stromal sarcoma on Thinprep. Diagn Cytopathol. 2015 Sep;43(9):756–62. Wang CW, Wu TI, Yu CT, Wu YC, Teng YH, Chin SY, et al. Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. Am J Clin Pathol. 2009 May;131(5):715–22. Mills AM, Dirks DC, Poulter MD, Mills SE, Stoler MH. HR-HPV E6/E7 mRNA in situ hybridization: validation against PCR, DNA in situ hybridization, and p16 immunohistochemistry in 102 samples of cervical, vulvar, anal, and head and neck neoplasia. Am J Surg Pathol. 2017 May;41(5):607–15. Karamurzin YS, Kiyokawa T, Parkash V, Jotwani AR, Patel P, Pike MC, et al. Gastric-type endocervical adenocarcinoma: an aggressive tumor with unusual metastatic patterns and poor prognosis. Am J Surg Pathol. 2015 Nov;39(11):1449–57. Kojima A, Mikami Y, Sudo T, Yamaguchi S, Kusanagi Y, Ito M, et al. Gastric morphology and immunophenotype predict poor outcome in mucinous adenocarcinoma of the uterine cervix. Am J Surg Pathol. 2007 May;31(5):664–72. Turashvili G, Morency EG, Kracun M, DeLair DF, Chiang S, Soslow RA, et al. Morphologic features of gastric-type cervical adenocarcinoma in small surgical and cytology specimens. Int J Gynecol Pathol. 2019 May;38(3):263–75. Mikami Y, Minamiguchi S, Teramoto N, Nagura M, Haga H, Konishi I. Carbonic anhydrase type IX expression in lobular endocervical glandular hyperplasia and gastric-type adenocarcinoma of the uterine cervix. Pathol Res Pract. 2013 Mar;209(3):173–8. Article / Publication Details

First-Page Preview

Abstract of Fine Needle Aspiration

Received: September 22, 2022
Accepted: January 17, 2023
Published online: March 14, 2023
Issue release date:

Number of Print Pages: 17
Number of Figures: 9
Number of Tables: 1

ISSN: 0001-5547 (Print)
eISSN: 1938-2650 (Online)

For additional information: https://www.karger.com/ACY

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif